A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502381-25-01

Acronym

CKFA115A12101

Enrollment

Registered

2024-01-25

Start date

2024-03-15

Completion date

Unknown

Last updated

2025-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal Cancer, Clear Cell Renal Cell Carcinoma, Cutaneous melanoma, Epithelial Ovarian Cancer, Esophagogastric Cancer, Head and Neck Squamous Cell Carcinoma, Mesothelioma, Microsatellite Instability High Colorectal Cancer, Nasopharyngeal Cancer, Non-small cell lung cancer, Thymic Carcinoma, Triple negative breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France, Germany, Italy, Spain

Outcome results